United States Cancer Tumor Profiling Market valuation $24.62 billion by 2033 - Exclusive Report by DatamIntelligence

"The global cancer tumor profiling market size reached US$ 10.98 Billion in 2024 from US$ 10.12 Billion in 2023 and is expected to reach US$ 24.62 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/cancer-tumor-profiling-market?sp

United States: Recent Industry Developments

✅ In October 2025, Foundation Medicine USA launched an expanded tumor profiling panel that integrates genomic and proteomic data for personalized oncology treatment, enhancing precision medicine capabilities.

✅ In September 2025, Tempus Labs USA completed the acquisition of a genomic profiling startup specializing in comprehensive tumor sequencing, strengthening its cancer diagnostics portfolio and accelerating R&D initiatives.

✅ In August 2025, Caris Life Sciences received FDA approval for its next-generation tumor profiling assay, enabling broader clinical adoption and supporting targeted therapy decision-making.

✅ In July 2025, Guardant Health USA invested in AI-driven tumor profiling platforms for liquid biopsies, improving detection of actionable mutations and supporting noninvasive precision oncology solutions.

Japan: Recent Industry Developments

✅ In October 2025, Sysmex Corporation launched comprehensive tumor profiling assays combining genetic and protein markers for early detection and personalized treatment strategies, reinforcing its diagnostic leadership.

✅ In September 2025, Fujifilm Japan completed a strategic partnership with a domestic molecular diagnostics firm to develop advanced tumor profiling technologies for precision oncology applications.

✅ In August 2025, Olympus Corporation received regulatory approvals for tumor profiling assays used in clinical oncology, ensuring compliance and wider adoption in Japanese healthcare settings.

✅ In July 2025, Roche Diagnostics Japan introduced AI-assisted tumor profiling solutions for precision medicine, enhancing mutation detection and personalized therapy guidance.

Cancer Tumor Profiling Market: Drivers

The cancer tumor profiling market is witnessing significant growth as personalized medicine and targeted therapies gain prominence in oncology. Tumor profiling involves analyzing genetic, proteomic, and molecular characteristics of cancer cells to guide treatment selection, predict disease progression, and monitor therapy response. Rising cancer prevalence, increasing awareness about precision medicine, and the need for tailored treatment strategies are driving market adoption. Technological advancements in next-generation sequencing (NGS), bioinformatics, and multi-omics analysis are enhancing profiling accuracy, depth, and clinical relevance. Additionally, growing investments by healthcare providers, research institutions, and pharmaceutical companies are further supporting market expansion.

Integration of tumor profiling with targeted therapies, immunotherapies, and clinical decision support systems is improving treatment outcomes and reducing adverse effects. Companies are developing comprehensive, multi-gene panels and liquid biopsy solutions to enable minimally invasive and rapid profiling. Rising collaborations between biotech firms, hospitals, and diagnostic laboratories are accelerating innovation and accessibility of advanced profiling tools. The increasing emphasis on early detection, precision oncology, and cost-effective cancer management is fueling demand. With continuous technological innovation, growing adoption of personalized medicine, and rising cancer incidence, the cancer tumor profiling market is poised for strong and sustained growth in the coming years.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-tumor-profiling-market?sp

Cancer Tumor Profiling Market: Major Players

F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Inc, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Caris Life Sciences., Guardant Health, NanoString Technologies (a Bruker Company), Foundation Medicine, Inc., and Paragon Genomics

Segment Covered in the Cancer Tumor Profiling Market:

➥ By Product Type: Kits and Consumables, Devices

➥ By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemias, Melanoma, Others

➥ By Technology Type: Immunoassay, Next-Generation Sequencing, Liquid Biopsy, Polymerase Chain Reaction, In-Situ Hybridization, Microarray, Others

➥ By Biomarker Type: Genomic Biomarkers, Protein Biomarkers, Others

➥ By Application: Clinical Applications, Research Applications

➥ By End-User: Hospitals, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research and Educational Institutions, Others

Research Process:

Both primary and secondary data sources have been used in the Cancer Tumor Profiling Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Cancer Tumor Profiling Market Research Industry:

➠ Who leads the Cancer Tumor Profiling industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Cancer Tumor Profiling market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Cancer Tumor Profiling market growth?
➠ What are the dominant sales and distribution strategies in the Cancer Tumor Profiling industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-tumor-profiling-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.